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2.   Summary 
The importance of maternal thyroxine for the development of the fetus brain early in 
pregnancy has received increasing acceptance. It has more recently become evident that 
maternal hypothyroxinemia results in the birth of children with decreased mental and 
psychomotor development. 
In our group of 7,530 women in 9-11 week of pregnancy were determined TSH, anti 
TPOAb and FT4. For evaluation of results was necessary to set reference intervals for 
pregnant women. 
The TSH reference interval was determined to be 0.06 - 3.67 mU/l and for FT4 9.8 - 23.43 
pmol/l was used. The limit for anti-TPO positivity was determined to be 143 kU/l.  
A raised concentration of TSH was found in 5.14% of women; and a suppression of TSH 
was found in 2.90% of women and 11.5% of pregnant women were found positive. 
Serum concentrations of FT4 were lower in TPOAb positive as compared to TPOAb 
negative women and differences of FT4 in euthyroid women with suppressed, normal and 
elevated TSH were found. 
In the study group there was no significant (p<0.05) difference in TSH or anti-TPO 
concentration in the groups, separated by age. 
           Physical examination, family and personal history and laboratory data were analysed in 
318 from 1205 women with any positivity (TSH higher than 3.67  or lower than 0.06 mIU/l, 
positive anti TPOAb), and thyroid ultrasound (TUS) was realised. In this positive group had 
been diagnosed 60.4 % women with subclinical hypothyroidism, 4.7 % with manifest 
hypothyroidism and 21.7 % had suppressed TSH - most probably owing to a high 
concentration of hCG. The next finding was 2.8 % of thyreotoxicosis and also two cases of 
adenomyosis and one papillary carcinoma of thyroid gland. In all, 67.9 % of positive women 
were treated by any medication. 82.6 % of women treated for hypofunction were anti-TPO 
positive.  
   In Czech Republic, case finding screening is able to disclose only about 20% of 
asymptomatic mild or deep hypothyroidism or women with positive anti TPO in pregnancy. 
Foreign study report 70% of these high-risk pregnant women, consequently is evident need of 
general screening of pregnancy thyroid failure in Czech Republic. Moreover the investigation of 
TSH, FT4 and anti TPO together is necessary.  
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3. Abbreviation 
  
anti -TPO thyroid peroxidise antibodies 
anti TG thyroglobulin antibodies 
FT44  free thyroxine 
free β hCG free beta subunit of hCG 
hCG  human choriogonadotropin 
IQ  intelligence quotient 
M  mean 
Mdn  median 
N  number 
NACB  the National Academy of Clinical Biochemistry 
PAPP–A         pregnancy–associated plasma protein A 
SD  standard deviation 
T3  trijodtyronin 
T4  thyroxin 
TG  thyreoglobulin 
TSH  thyroid stimulating hormone 
TUS  thyroid ultrasound 
VZP   General Health Insurance Company  
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4. Introduction 
Many changes in the functioning of the thyroid gland occur during pregnancy and some 
diseases of the thyroid gland can affect both the pregnant woman and the fetus. 
Hypothyroidism is the most serious disorder of those occurring during pregnancy, and it 
might go unnoticed as some ‘nonspecific’ problem. Pregnant women with subclinical 
hypothyroidism seem to escape early clinical detection. The implications are staggering when 
one considers that there is a significant increase in intrauterine deaths, spontaneous abortions, 
premature births, and pre-eclampsia; also the development of the fetus, such as major 
malformations and loss of IQ. While the hyperfunction during pregnancy usually manifests 
itself by clinical symptoms or a relapse of a previously cured disease (mostly Graves - 
Basedow), lowered functioning is much more dangerous because of its non-specific 
symptoms. It has been clearly proven that even slight (subclinical) hypothyroidism affects not 
only the course of pregnancy, but (especially later-on) the neuropsychological development of 
the child. Symptoms of hypothyroidism (fatigue, lowered performance, sleepiness, 
psychological lability) can also accompany the physiological pregnancy; some women with 
subclinical hypothyroidism are absolutely asymptomatic and there is no reliance on the 
clinical image, while diagnostic of functional failure.  
Results of surface population screenings are slightly varied, depending upon on level of 
medical care and approach to prevention, geographical conditions, supplementing with iodine, 
and other circumstances (including used diagnostic criteria). Evaluating thyroidal function 
during pregnancy is difficult, considering the other differing influences of pregnancy. 
Determining TSH in the serum is a basic searching procedure in the diagnosis of function of 
the thyroid gland in the general population. Its regulation is based on feedback, however 
during pregnancy there are also other mechanisms taking place - mainly there is suppression 
of TSH, presumably due to a slight increases in the free thyroxin concentration driven by high 
hCG values.  
By using the classical reference range for serum TSH one might misdiagnose as 
healthy those women who already have a slight TSH elevation and, conversely, one might 
suspect hyperthyroidism in normal women who have a lowered serum TSH value.  
Determining the reference range suitable for the 1st trimester of pregnancy is possible 
by using the suggestion of the National Academy of Clinical Biochemistry (NACB) on 
selected samples from the population, or as 95th percentile from the cohort of women. 
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Determining FT4 is by watching the amount of biologically active hormone which is 
available to the organism of a pregnant woman (as well as the fetus), and is not affected by 
the concentration of binding proteins. Its concentration during pregnancy is partly effected by 
inflow of iodine and the duration of the pregnancy. Some consider it even more informative 
than TSH during pregnancy. During the 1st trimester, the fetus is completely dependent upon 
thyroxin produced by the mother. Even a small unnoticed malfunction of the thyroid gland, 
which doesn’t have to endanger the course of the pregnancy, can affect the psychomotor 
development of the child. Early maternal hypothyroxinemia alters histogenesis and cerebral 
cortex cytoarchitecture of the progeny. 
Anti-TPO antibodies are markers of autoimmune process in the thyroid gland, their 
determination is diagnostically and prognostically important. Presence of anti-TPO during 
pregnancy also alerts to the danger of development of postpartum tyreoiditidis; about 50% of 
anti-TPO positive women have some thyroid dysfunction after delivery, so it is necessary to 
follow-up these women. 
The recommended dietary allowance for nonpregnant, nonlactating women aged 14 year 
is 150 µg/d. The iodine requirement during pregnancy is sharply elevated because of an 
increase in maternal thyroxine production to maintain maternal euthyroidism and to transfer 
thyroid hormone to the fetus, iodine needs to be transferred to the fetus for fetal thyroid 
hormone production in later gestation and a probable increase in renal iodine clearance. The 
recommended dietary allowance for pregnancy is 220 µg/d. In Czech Republic has been 
iodized salt in regular use since the 1950s, a good level of iodine supplementation can be 
expected also on Zamrazil (2004) study. 
Malfunction of the thyroid gland during pregnancy is long-term, and still not a sufficiently 
solved problem. On many pages of scientific literature and specialist literature there are still 
new arguments to systematically screen pregnant women for thyroid underfunction and 
asymptomatic chronic thyroiditis in order to give such women the appropriate treatment.  
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5. Aims 
 
The aim of this study was to introduce an estimation of thyroid dysfunction during 
pregnancy, selection of suitable analytic methods and determination of reference intervals for 
these markers in pregnancy.  
 
 
1. The selection of efficient combination of methods for detection of thyroid dysfunction 
and the suitable term for investigation during pregnancy. Assess the interferences of 
other parameters, especially effect of high level of hCG on TSH. 
2. Determination of the reference intervals for selected markers in the first trimester of    
pregnancy in plentiful group of pregnant women.  
3. Defined reference intervals use to assign the percentage of thyroid dysfunction in the 
population of pregnant women who are undergoing their first trimester prenatal 
screening of the Down syndrome. These women devolve on endocrinologist and 
especially pregnant women with anti-TPO positivity follow up also postpartum. 
4. Verify statement about increased incidence of thyroid dysfunction in older pregnant 
women. 
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6. Material and Methods 
6.1 Studied groups 
The study group (nonselected-NS) consisted of 7,350 pregnant women (in their 9th – 11th 
week of pregnancy, 99% Caucasian) who were undergoing their first trimester prenatal 
screening in the Institute of Clinical Biochemistry and Laboratory Diagnostics of Charles 
University, Prague, Czech Republic. Blood samples were collected non-contactly and 
centrifuged for 10 min after temperature reduction and formation of the clot. The serum was 
removed and after free β hCG and PAPP-A (for first trimester screening) determination were 
serum assayed for TSH and anti-TPO. FT4 was determined only in the case of TSH or anti-
TPO out of the reference interval. The exact iodine status of this study group is not known. 
All participating pregnant women gave informed written consent wit this subsequent 
investigation. 
1) For evaluation of the reference interval, a selected group (S1) was created in 
accordance with the recommendations of the National Academy of Clinical 
Biochemistry (NACB). From the group of pregnant women, all those with a history of 
thyroid disease were excluded; anti-TPO > 60 kU/l (the manufacturer's cut-off) and 
free β hCG higher than triple of the median (Mdn=56.6 µg/l), in view of the 
suppression of TSH by a high level of hCG, were also excluded. Data for the other 
recommendation of the NACB - a family history of thyroid disease for the selection of 
women – were not accessible. 
2) For the determination of pregnancy cut-off for anti-TPO, a selected group (S2) was 
created. From all of the women, women with a known history of thyroid disease were 
separated, as well as those with TSH lower than 0.06 and higher than 3.67 mU/l our 
new reference interval for TSH in the first trimester of pregnancy. 
3) The entire nonselected group was divided into separate subgroups by age. The 
Tukey test was applied for determination of the statistical significance of differences 
with TSH and anti-TPO levels. The control group (C) for the evaluation of mean age 
was created by using pregnant women with TSH between 0.06 - 3.67 mU/l (our new 
reference interval) and with anti-TPO under the manufacturer’s reference interval of 
60 kU/l. 
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6.2 Immunoanalytical methods  
6.2.1 Determination of TSH, anti-TPO, and FT4  
were assayed by ADVIA® Centaur™ (Siemens), with chemiluminometric detection. TSH 
was determined by sandwich imunoanalysis with direct chemiluminometric technology; for 
anti-TPO and FT4 competitive imunoanalysis with direct chemiluminometric technology was 
used.  
Reproducibility of this method is expressed by the interassay variability. For TSH, it is 5 - 7% 
for levels of 0.43 – 15.00 mU/l; for anti-TPO it is 10% for the level of 70 kU/l and 7% for the 
level of 170 kU/l. Interassay variability for FT4 is 7 - 9% for levels 10.1 - 33.0 pmol/l. 
 
6.2.2 Determination of free β hCG  
Free β hCG was assayed on a BRAHMS KRYPTOR. This system uses the TRACE (Time 
Resolved Amplified Cryptate Emission) technology, based upon a non-radiative transfer of 
energy. This transfer takes place between two fluorescent tracers: a donor (europium cryptate) 
and an acceptor named XL665 (a phycobilisome obtained from red algae). In the 
immunometric assay both are bound to an antibody.  
Interassay variability for free β hCG is 3.0% 
 
 
6.3 Statistical evaluation 
The statistical analysis was performed using Statistica 7.1 CZ software (StatSoft, Prague 
6, Czech Republic). All values are reported as mean±standard deviation or as shift 
percentages.  
TSH and anti-TPO do not follow a normal distribution, they have to be normalized using 
log transformation. The reference interval was than determined using this log transformed 
data and geometric means are used to describe the means. 
One way ANOVA and post-hoc p-levels for the Tukey honest significant difference 
(HSD) were considered to be statistically significant at the p< 0.05 level. 
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7. Results 
7.1 Suppress of TSH level by high hCG 
The mean free β hCG of women with suppressed TSH is double, in comparison with 
the group with a normal or higher TSH. One way ANOVA test at the p< 0.05 level was 
statistically significant for differences between the mean of free β hCG, for groups with 
different TSH levels. The results of the statistical analysis are shown in Figure 1. On the other 
hand, differences between groups with normal and higher TSH are not statistically significant.  
 
Figure 1 Free β hCG in groups with different TSH level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human chorionic gonadotropin (hCG) free β-subunit measurement is used together with 
pregnancy associated protein A (PAPP-A) as a screening test for Down syndrome during first 
trimester of pregnancy. Difficulties arise mainly from low stability of free β-hCG subunit. 
Our study of stability free β hCG in real condition of collection and transport blood samples  
shows that results are reliable, when samples of free β hCG are separated immediately, (max. 
4 h after drawing) stored at 2 – 8oC and analyzed within 2 days.  
 
 
 
< 0,06 0,06 - 3,67 >3,67
TSH (mU/l)
40
50
60
70
80
90
100
110
120
fre
e 
β h
C
G
 
(µg
/l)
 13 
7.2 Reference intervals and decision limits in first trimester of pregnancy 
7.2.1 Determination of TSH reference interval 
The nonselected group (NS), as well as the selected group S1, were statistical analyzed, 
and results for all years together are shown in Table 1. Group S1 was composed of pregnant 
women with no history of thyroid disease, anti-TPO level lower than 60 kU/l and free β hCG 
lower than triple of the median (Mdn=56.6 µg/l) 
An acceptable reference interval for TSH in pregnant women was selected like 2.5th percentile 
for lower and 97.5th percentile of the selected group S1 (0.06 - 3.67 mU/l). A very similar 
upper limit was founded by using the 95th percentile of the nonselected group (NS) (3.71 
mU/l). 
 
Table 1 Reference ranges of TSH in pregnancy for nonselected (NS) and selected (S1) groups 
of pregnant women 
TSH 
mU/l N  Median Min. Max. 
2.5th  
percentile 
5th 
percentile 
95th 
percentile 
 97.5th  
percentile 
NS 5520 1.280 0 411.874 0.048 0.147 3.713 4.796 
S1 4337 1.213 0 11.534 0.062 0.154 3.144 3.670 
 
7.2.2 Determination of FT4 reference interval 
FT4 was determined only for women (n=1176) with TSH lower than 0.1, and higher than 
3.00 mU/l (or anti-TPO higher than 60 kU/l). For FT4 we used our reference interval of 9.8 - 
23.43 pmol/l the manufacturer’s one (9.8 - 23.1 pmol/l) for all populations. Statistical 
evaluation of FT4 results is shown in Table 2. 
 
Table 2 Statistical evaluation of FT4 
N  mean Median Min. Max. 2,5th percentile 97,5th percentile 
1176 14,77 14,13 4,67 44,46 9,8 23,43 
 
Serum concentrations of FT4 were lower in TPOAb-positive group of pregnant 
women (median 13.79 pmol/l), in TPOAb-negative group  were median 15.18 pmol/l These 
differences was significant on P<0.001. The median of FT4 level in euthyroid women with 
suppressed TSH was 17.89 pmol/l, with normal  TSH was 13.98 pmol/l and in group of 
women with elevated TSH was median 12.91 pmol/l. The differences was significant at  
P<0.05. 
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7.2.3 Determination of anti TPO cut-off 
The selected group S2 (pregnant women with no history of thyroid disease and with TSH 
level between 0.06 and 3.67 mU/l), as well as nonselected group, were statistical analyzed and 
the results for all years together are shown in Table 3.  
 
Table 3 Cut-off of anti-TPO antibody for nonselected (NS) and selected (S2) groups of 
pregnant women. 
Anti TPO 
(kU/l) N  Median Min. Max. 
5th 
percentile 
95th 
percentile 
90th 
percentile 
NS 5520 38 0 15000 8 908 196 
S2 5281 37 0 15000 8 577 143 
 
The decision limit for the recommendation to visit an endocrinologist was determined to be 
143 kU/l anti-TPO.  
 
7.3 Detection of thyroid diseases in pregnancy in Czech population  
Evaluation of positive results for the TSH reference interval created at the 2.5th, 5th, 95th and 
97.5th percentile of the selected group S1 (S1 – pregnant women with no history of thyroid 
disease, anti-TPO level lower than 60 kU/l and free β hCG lower than triple of the median 
(Mdn=56.6 µg/l) are presented in Table 4.  
In our group of pregnant women, 2.90% had a low level of TSH; 5.14% had TSH over the 
reference interval.  
Table 4: Distribution of TSH in groups of women in the 1st trimester of pregnancy by 
different reference interval (percentile of selected group S1). 
  TSH mU/l N % 
< 2.5th percentile 
< 0,062 214 2,9 
< 5th percentile 
< 0,154 378 5,14 
> 95th percentile 
> 3,144 592 8,05 
> 97.5th percentile 
> 3,670 378 5,14 
 
The selected group (S2), as well as nonselected group, were statistical analyzed and 
the results with anti-TPO positivity for each year as well as all together are shown in Table 5. 
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Using the manufacturer's cut-off level we found 20.6% of the women to be with positive anti-
TPO antibodies; using our decision value (143 kU/l) it was 11.5%  
 
Table 5: Anti-TPO positivity for manufacturer's cut-off and for our pregnacy cut-off 
anti TPO (kU/l) N > 60 kU/l % N > 143 kU/l % 
All 1506 20,6 851 11,5 
2005 289 32,11 99 11 
2006 356 27,77 157 12,25 
2007 377 16,85 237 10,59 
2008 456 17,96 338 11,76 
2009 28 19,36 20 10,26 
 
There were 35 (0.48%) women with FT4 under and 28 (0.37%) women with FT4 over the 
reference range. The mean level in the group in reference interval of FT4 was 14,55 ±2,44 
pmol/l. 
 
7.3.1  Positivity in study group of pregnant women 
Physical examination, family and personal history and laboratory data were analysed 
in 318 from 1205 positively screened women (TSH>3.67 mIU/l and/or positive TPOAb), and 
thyroid ultrasound was realised. 
Women with any positivity of thyroid dysfunction were informed and half of them visited the 
endocrinologist within 1-4 weeks, the rest between 8-20 weeks. Structure of diagnosis in 
group of 318 women which were follow up in hospital endocrinology is in the Table 6. 
 
Table 6: Structure of diagnosis in group of positive women  
subclinical hypothyroidism 60,4% 
overt hypothyroidism 4,7% 
hyperthyroidism 2,9% 
thyroid cancer 2,8% 
without malfunction 7,5% 
low TSH without malfunction 21,7% 
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There was no difference in TPOAb levels between women with positive and negative 
TUS. All women with elevated TSH were asymptomatic. Family and/or personal history of 
thyroid diseases and/or autoimmune diseases were present in 21.9 % of them.  
 
7.3.2 Anti-TPOAb positivity and TSH level 
Higher TSH is also very often associated with positivity of anti-TPO antibodies. In the 
group with TSH > 3.67 mU/l there were 44.1% of women with antibody positivity (anti-TPO 
> 143 kU/l); and in groups with TSH <0.06 mU/l, or in the pregnancy reference range only 
10.1% or 9.1% of the women are with antibody positivity. One way ANOVA test at the 
p < 0.05 level was statistically significant for differences between the levels of anti-TPO for 
groups with different TSH level. Level of anti-TPO in the group with higher TSH is 
significantly higher at p < 0.050; differences between groups with low (or normal) TSH are 
not statistically significant and there are showed on Figure 2. 
 
 
Figure 2:  Anti TPO in groups with different TSH level 
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7.4 The influence of age over anti-TPO antibodies positivity and high TSH 
The average age in the noneselected group (NS) was 31.3 (+/- 4.6); in the control 
group (C) of pregnant women it was 31.2 (+/- 4.3) years. One way ANOVA analysis 
confirmed no statistically significant differences in the average age, at the p < 0.05 level, 
between groups with different TSH and anti-TPO levels.  
The average age in the groups with different TSH and anti-TPO levels are shown in Table 7.  
Table 7: Mean age of pregnant women by different TSH and anti-TPO concentrations 
TSH (mU/l) N mean age SD  anti-TPO (kU/l) N mean age SD 
<0.06 158 31.4 0.451  < 60 4470 31.1 0.081 
0.06 - 3.67 5096 31.1 0.075  60 - 143 462 31.1 0.230 
>3.67 266 30.9 0.289  143 - 1000 344 31.6 0.300 
     > 1000 244 31.3 0.328 
 
There was no significant trend (p<0.05) for TSH or anti-TPO levels to rise with increasing 
age in the women.  
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8. Discussion 
8.1 Suppress of TSH level by high hCG 
Suppressed serum TSH concentration during gestation follow hyperthyroidism as well 
as hyperemesis gravidarum or high hCG levels. Lower serum TSH in pregnancy is influenced 
by the thyrotropic activity of elevated circulating human chorionic gonadotropin 
concentrations, mainly in the first trimester. In study group of pregnant women with 
suppressed TSH the average level of hCG was almost double (M=95.6 mg/ml) in comparison 
with group with TSH in reference range (M=68.9 mg/ml) or with TSH >3.67mU/l (M=62.1 
mg/ml). Differences between the normal and raised TSH groups in hCG levels were not 
significant at p<0.050. In 1990, Glinoer and his associates examined distributions of maternal 
TSH measurements throughout pregnancy.They documented a downward shift in TSH levels 
during the first trimester – attributable to a weak TSH-like effect of hCG – followed by a 
gradual rise as pregnancy proceeded. The pattern of TSH measurements described in this 
study for the first trimesters is consistent with his work. The other authors also confirm that 
sub-normal serum TSH levels in the first trimester are coincident with rising hCG levels.  
 
8.2 Reference intervals and decision limits in first trimester of pregnancy 
Determination of the specific reference intervals for TSH, FT4, and anti-TPO during 
pregnancy is one of the basic requirements when implementing a general examination of the 
thyroid gland in early pregnancy. Reference intervals for different methods and 
manufacturer’s may vary, they have been established using pools of nonpregnant normal sera 
and with different antibodies. Such reference ranges are not valid during pregnancy. A 
reference interval is the range of values of a test result for a defined population. The range is 
usually specified as the central 95% of the values, from the lower 2.5% to the upper 97.5% of 
the population. In older references the reference interval is often designated as the reference 
range. 
For determination of reference intervals various methods are used. Haddow (2004) 
used for TSH the 98th percentile in the entire group or anti-TPO negative woman. This cut-off 
resulted to 4.3% of first trimester women being identified as high risk. To achieve intended 
target of 2% (based on clinical correlation), they would need to set the cut-off higher. Vaidya 
(2006) used reference range based on the squared 95% confidence intervals in anti-TPO 
negative woman for TSH and FT4. TSH and anti-TPO have to be normalized using log 
transformation, as they do not follow a normal distribution. The National Academy of Clinical 
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Biochemistry (NACB) guidelines are commonly used and TSH reference intervals are 
established from the 95% confidence limits of the log-transformed values of anti TPO Ab-
negative, ambulatory, euthyroid subjects who have no personal (or family) history of thyroid 
dysfunction and no visible goiter.  
The manufacturer’s reference range for in laboratory used TSH method 
(ADVIA:Centaur Siemens) is 0.37 - 5.00 mU/l. For the 1st trimester, the specific reference 
range was used the 2.5th and 97.5th percentile of the selected group S1, without anti-TPO 
positive and woman with hCG > triple of the median. The reference ranges for TSH were 
established upon 0.06 - 3.67 mU/l. When was used, for evaluation, the 95th percentile in the 
group of nonselected samples, the upper limit was 3.71 mU/l. Vaidya (2006) calculated for 
the TSH reference range 0.09 - 3.03 mU/l, in comparison to manufacturer’s interval 0.27 - 
4.20 mU/l. The other authors apply the manufacturer’s or their own reference range for TSH, 
which vary from 2.0 to 5.0 mU/l. Serum TSH values are dependent on the method used and 
each laboratory should establish a trimester-specific reference range for pregnant women. 
FT4 levels fit a Gaussian distribution, so reference ranges were derived using 
nonparametric analyses such as the 95th percentile. The calculated reference interval 9.8 - 
23.43 pmol/l was very similar to the manufacturer’s interval of 9.8 - 23.0 pmol/l. In this study 
was measured FT4 only in case of positivity anti-TPO, or if TSH was out of the reference 
range. It is recommended to keep the level of FT4 in pregnancy over half of the reference 
range. 
Differences in anti-TPO antibody manufacturer’s reference range are incomparable: 
from 0.5 to 100 kU/l. NACB stresses that the reference intervals for thyroid peroxidase 
antibodies (anti TPO) should be based on young men who lack certain risk factors and have 
serum TSH between 0.5 and 2.0 mIU/L. In this study was calculated the reference interval at 
the 90th percentile from the selected group S2, with a TSH level in new established pregnancy 
specific range of 0.06 – 3.67 mU/l. The anti-TPO positivity cut-off was established to 143 
kU/l.  
 
8.3 Detection of thyroid diseases in pregnancy in Czech population 
In the group of 7, 350 women, 213 (2.90%) had their TSH under the reference interval 
(<0.06 mU/l). The prevalence of hypertyreosis in pregnant women is 1.7%, and 0.4% of these 
women had an elevated serum FT4 level. This is similar to that reported for non-pregnant 
individuals.   
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Many authors have determined the prevalence of hypothyreosis (overt and subclinical) 
in pregnancy and it is estimated to be 0.3 - 0.5% for overt hypothyroidism and 2 - 3% for 
subclinical hypothyroidism. In this study there were 4.5% of pregnant women with TSH over 
reference interval (>3.67 mU/l); which is in concordance with previous hypotheses, as well as 
with Haddow (2004) who used their own reference interval, identifing 4.3% of pregnant 
women with high TSH levels.  
The positivity of anti-TPO in nonpregnant individuals is about 11%; in the pregnant 
population it is very similar. Negro (2006) mentioned 11.7% anti-TPO positive pregnant 
women; Dossiou (2008) selected groups by age and the positivity was 10.4 and 12.6 for ages 
25 and 35 years, respectively. When was used the reference interval recommended by the 
producer of reagents (> 60 kU/l), there was 22.1% positivity. If was used the 90th percentile 
(143 kU/l) as the cut-off for our group of pregnant women, there was 11.5% positivity in 
group with no age differentiation. These results correlate very well with other studies. 
Pregnant women with anti-TPO between 60 and 143 kU/l were given notice to visit an 
endocrinologist after delivery; women who had anti TPO > 143 kU/l were invited to do so 
immediately.  
There exists a positive association between the presence of thyroid antibodies and 
pregnancy loss with postpartum thyroiditis. 
Presently available information that supports the hypothesis that an inappropriate first 
trimester surge in maternal FT4, whatever the circulating TSH, would interfere with the 
development of the cerebral cortex, even if maternal euthyroidism is maintained by normal 
circulating T3. There is at present increasing consensus (Morreale, 2004) that maternal 
hypothyroidism, both clinical and subclinical, requires early detection and prompt treatment, 
because of its important negative effects for the woman, the pregnancy and the child. 
The most practical approach is to screen all pregnant women for hypothyroidism as 
early in pregnancy as possible (or before conception). In the case of the mother, screening 
would reset in early diagnosis and treatment of subclinical hypothyroidism. Unfortunately, 
pregnant women with subclinical hypothyroidism seem to escape early clinical detection. In 
Mitchel (2004) study, 58% of the hypothyroid women were unaware of their disorder, and it 
took a median of 5 years from the time of the pregnancy for the clinical diagnosis to be made.  
Vaidya (2007) study shows that targeted thyroid function testing of only high-risk 
pregnant women would miss nearly one-third of women with overt/subclinical 
hypothyroidism during early pregnancy. In Czech Republic, case finding screening is able to 
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disclose less than 20% of asymptomatic mild or deep hypothyroidism or women with positive 
TPOAb in pregnancy. 
 The relationship between anti-TPO and TSH is not definite, despite it being known 
that women with high level of TSH more frequently have positive anti-TPO antibodies. In 
study group, divided by serum TSH concentration, were 44.1% anti-TPO positive (in part), 
with TSH >3.67 mU/l and 10.1% or 9.15% in the group with TSH < 0.06 mU/l or TSH in the 
reference interval. Glinoer (1990) also documented somewhat higher TSH levels among the 
sub-population of women with elevated antibody levels and these findings are confirmed in 
the present study. 
 
8.4 The influence of age over anti-TPO antibodies and high TSH 
 The greater the pregnant women’s age very often is a reference risk factor of thyroid 
malfunction. Stricker (2007) published that the anti-TPO level was related to maternal age. 
Negro (2006) presented a higher prevalence of anti-TPO positivity in older women, and the 
NHANES III study shows slightly increasing levels of TSH and anti-TPO with age. In 
contrast to these, in this study was did not find a significant (p < 0.05) difference between the 
average age of the pregnant women with positive anti-TPO and those with low TSH (or in the 
reference interval). There is also no significant (p<0.05) difference in TSH or anti-TPO 
concentration in groups, separated by age. It is possible that this is because 76% of those 
pregnant women were within the ages of 25 - 35. 
 
An answer to the question of screening cost-effectiveness of thyroid function in pregnancy 
was already presented by Dosiou (2008). In our study is not defined cost-efficiency, but it is 
unquestioned fact that early diagnosis of thyroid disorder is cost-effective and beneficial for 
both mother and child. 
 Maternal hypothyroxinemia appears to be a much more frequent cause of deficits in 
the progeny than congenital hypothyroidism, for which we have successful neonatal thyroid 
screening programs. This study maybe will help define the impact of universal screening 
(TSH, FT4, anti-TPO) on the health care system. The other analysis would be more clearly 
identify the causal relationships between mild thyroid hormone deficiency and thyroid 
autoimmunity, on the one hand, and fetal neurological development on the other. In the 
meantime, physicians and obstetricians must use their own judgment about the optimal 
management for their individual patients. 
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9. Conclusion 
1. In the group of 7,350 women (in their 9th – 11th week of pregnancy) who were 
undergoing their first trimester prenatal screening were serum assayed (with informed 
consent) for TSH, anti-TPO, resp. FT4. Determining TSH in the serum is a basic 
search procedure in the diagnosis of the thyroid gland function. Determination of FT4 
is by watching the amount of biologically active hormone which is available to the 
organism of a pregnant woman (as well as the fetus), and is not affected by the 
concentration of binding proteins. Anti-TPO antibodies are markers of autoimmune 
process in the thyroid gland, the presence of anti-TPO during pregnancy also alerts 
one to the danger of development of postpartum tyreoiditidis. 
FT4 concentration during pregnancy is partly effected by both the inflow of iodine 
and the duration of the pregnancy. TSH regulation is based on feedback; however, 
during pregnancy there are also other mechanisms taking place - mainly suppression 
of TSH, presumably due to the thyroid-stimulating activity of hCG early in pregnancy 
when hCG levels are highest. We studied the stability of free β hCG in maternal blood 
upon storage and during sample transport. Serum for Down syndrome screening 
should be separated till 2 hours after collection, stored at 2 – 8oC and analyzed within 
2 days. 
The post-hoc analysis of our results by application of the Tukey HSD test showed 
statistical significant differences between means of free β hCG in the group with low 
TSH (< 0.06 mU/l), and in groups with normal or higher TSH. Lower TSH level in the 
first trimester is significant only if other markers (FT4 or anti-TPO) are out reference 
interval too. 
2. For the right evaluation of our results we determined the reference intervals for 
TSH, anti TPO, and FT4 in the first trimester of pregnancy. TSH and anti-TPO do not 
follow a normal distribution, they have to be normalized using log transformation. An 
acceptable reference interval for TSH in pregnant women (0.06 - 3.67 mU/l) we 
selected like 2.5th percentile for lower and 97.5th percentile of the group S1 (pregnant 
women with no history of thyroid disease, anti-TPO level lower than 60 kU/l and free 
β hCG lower than triple of the median Mdn=56.6 µg/l). In this study was calculated 
the decision limit for anti-TPO at the 90th percentile from the selected group S2 
(pregnant women with no history of thyroid disease and with TSH level between 0.06 
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and 3.67 mU/l),with a TSH level in new established pregnancy specific range of 0.06 
– 3.67 mU/l. The anti-TPO positivity cut-off we established to 143 kU/l. FT4 levels fit 
a Gaussian distribution, so reference ranges we derived using nonparametric analyses 
such as the 95th percentile. The reference interval was 9.8 - 23.43 pmol/l. 
3. In all our study group 7,350 women were 1205 with any positivity. There were 2.90 % 
women with low and 5.14 % with high TSH; 0.38 % with high and 0.48 % with low 
FT4. Positivity of anti-TPO antibodies in all of them was 11.5 %. About this 
abnormality we informed their attending physician, with approach to cooperative 
endocrinologist.   
318 of this 1205 women with TSH lower then 0.06 mU/l or higher then 3.67 mU/l or 
wit anti-TPO positivity were attending the 3rd Medical Department - Clinical 
Department of Endocrinology and Metabolism of General Teaching Hospital Prague.  
 Subclinical hypothyroidism was diagnosed in 60.4%, overt hypothyroidism in 4.7%, 
hyperthyroidism in 2.9% and thyroid cancer in 2.8% of 318 women. There was no 
difference in TPOAb levels between women with positive and negative TUS. All 
women with elevated TSH were asymptomatic. Family or personal history of thyroid 
or autoimmune diseases were present in 58.3% all of them. Women with subclinical 
hypothyroidism had family or personal history of thyroid or autoimmune diseases only 
in 21.9% of them. 
4. World guidelines for management of thyroid dysfunction during pregnancy and 
postpartum recommend not universal but only case finding screening. Our study 
strongly support the need of establishing mass screening programs for pregnant 
women early in gestation in the Czech Republic. Screening would result in early 
diagnosis and treatment of thyroid disease, and it is possible to combine with first 
trimester screening for Down’s Syndrome.  
5. In this study we did not find a significant difference between the average age of the 
pregnant women with positive anti-TPO and those with low TSH (or in the reference 
interval). There is also no significant difference in TSH or anti-TPO concentration in 
groups, separated by age. It is possible that this is because 76% of our pregnant 
women were within the ages of 25 - 35. 
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In 2009 is proving the system general testing of the insufficient function of the thyroid 
gland during early pregnancy by TSH, FT4 and anti-TPO levels determination in some parts 
of Czech Republic. This project is supported by the VZP (General Health Insurance 
Company), the biggest health insurance company in the Czech Republic.  
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